Martin S, Cantin E, Rouse B T
Department of Microbiology, College of Veterinary Medicine, University of Tennessee, Knoxville 37996-0845.
J Gen Virol. 1989 Jun;70 ( Pt 6):1359-70. doi: 10.1099/0022-1317-70-6-1359.
Immunization of mice with vaccinia virus recombinants expressing the glycoproteins B or D of herpes simplex virus type 1 (HSV-1) induced humoral antibody as well as multiple aspects of HSV-1-specific T lymphocyte-mediated responses. However, vaccinated mice were not completely resistant to HSV-1 challenge and were unable to eliminate an epithelial infection rapidly. Evidence is presented which indicates that immunization with either vaccinia virus recombinant, while inducing the necessary protective populations of CD4+ T lymphocytes, fails to induce the complementing CD8+ cytotoxic T lymphocytes necessary for high levels of protection against a primary HSV-1 infection. These findings are discussed with relevance to the future development of anti-HSV vaccines.
用表达1型单纯疱疹病毒（HSV-1）糖蛋白B或D的痘苗病毒重组体免疫小鼠，可诱导体液抗体以及HSV-1特异性T淋巴细胞介导反应的多个方面。然而，接种疫苗的小鼠对HSV-1攻击并未完全产生抗性，且无法迅速消除上皮感染。有证据表明，用任一痘苗病毒重组体免疫，虽能诱导产生必要的保护性CD4+ T淋巴细胞群体，但未能诱导出高水平抵御原发性HSV-1感染所需的互补性CD8+ 细胞毒性T淋巴细胞。结合抗HSV疫苗的未来发展对这些发现进行了讨论。
